Kyler T Falk On HubPages VerdeWatchesAs noted above, fewer patients in the earlier trials obtained statin therapy or revascularization after MI; these cures were much more common in recent trials. Potential interaction by background drugs was tested in the primary outcomes reviews of a few trials. One trial4 identified effect amendment by statin or β blocker use, although statistical power in these subgroup analyses was limited. 7,53Third, post hoc power calculations suggest that most recent trials in post MI patients were considerably underpowered to detect a clinically significant effect on CHD death, with even less power to detect an effect of omega 3 PUFA supplementation on the chance of SCD. 43 Several of those trials had to change and expand their primary end point during follow up because of lower than expected event rates. Indeed, the danger of recurrent events among contemporary patients with CHD events is way less than the corresponding risk of post MI patients from 15 to 20 years ago.